Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.
Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.
The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.
In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).
Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.
Oncolytics Biotech announced key operational highlights and financial results for Q1 2022, with a cash position of $39.5 million expected to fund upcoming milestones. The company reported positive clinical data for its lead drug, pelareorep, showing improved patient outcomes in HR+/HER2- breast cancer and successful combinations with CAR T therapies in preclinical studies. Operating expenses decreased from $3.1 million to $2.6 million year-over-year, though net loss increased to $6.8 million. Upcoming milestones include data from the BRACELET-1 study in Q4 2022.
On May 4, 2022, Oncolytics Biotech announced favorable results from its AWARE-1 study on pelareorep for HR+/HER2- breast cancer. The treatment demonstrated a 100% favorable Risk of Recurrence Score (ROR-S) in evaluable patients, up from 55% at baseline. Increases in tumor cell death markers and T cell activation were also noted. The study's findings support pelareorep's potential to enhance clinical outcomes by transforming tumors into less aggressive types. Future clinical trials, including BRACELET-1, aim to further evaluate its effectiveness.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced that its abstract, detailing results from the AWARE-1 study, has been accepted for presentation at the European Society for Medical Oncology Breast Cancer Meeting from May 3-5, 2022, in Berlin. The study evaluated the oncolytic virus pelareorep combined with letrozole and atezolizumab in early-stage breast cancer patients. Results suggest pelareorep may enhance immune responses and improve treatment outcomes. The presentation is scheduled for May 4, 2022, at 12:15 p.m. CET, focusing on innovative cancer therapies.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2022, at 5:00 p.m. ET to discuss its first-quarter financial results and corporate update. Pelareorep, an immunotherapeutic agent being developed by Oncolytics, is under evaluation for its efficacy in treating various cancers. The company is moving towards a registration study for metastatic breast cancer and is conducting clinical trials in combination with other therapies. Investors can access the webcast via the Investor Relations page on Oncolytics' website.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 11:00 a.m. ET in Toronto. The conference will feature updates from Canadian healthcare companies and offer one-on-one investor meetings. A live webcast of the presentation will be available on Oncolytics' Investor Relations page and archived for three months. The company focuses on developing the immunotherapeutic agent pelareorep to enhance anti-cancer immune responses.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the publication of preclinical data showing that pelareorep significantly enhances the efficacy of CAR T cell therapy in treating solid tumors. The study, published in Science Translational Medicine, demonstrates that pelareorep-loaded CAR T cells exhibit improved persistence and anti-cancer activity in various murine solid tumor models. This combination may address key challenges faced by CAR T therapies in solid tumors, potentially increasing treatment options for patients. The findings suggest a promising avenue for clinical application.
Oncolytics Biotech (NASDAQ: ONCY) will have its Chief Medical Officer, Thomas Heineman, participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Date: April 14, 2022
Time: 10:00 a.m. ET
Webcast: click here
Additionally, the company will engage in one-on-one investor meetings, highlighting its focus on developing pelareorep, an immunotherapeutic agent aimed at treating various cancers.
Oncolytics Biotech announced positive long-term results from the ReoGlio phase 1b trial, demonstrating pelareorep's potential in treating glioblastoma multiforme (GBM). A higher dose led to a median overall survival (mOS) of 50% at 24 months, with one patient alive at 42 months. The trial confirmed the treatment's favorable safety profile, supporting further studies. These findings suggest pelareorep may extend survival benefits beyond breast cancer to other challenging cancers. The results will be presented at the AACR Annual Meeting.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced new clinical data from a phase 1b trial of pelareorep in relapsed/refractory multiple myeloma patients. Notably, some patients achieved progression-free survival (PFS) exceeding three years despite prior treatment failures. This study illustrates pelareorep's ability to facilitate immune cell recruitment into the tumor microenvironment. The results increase understanding of pelareorep's mechanism and safety profile, paving the way for further clinical development in multiple cancers, including ongoing breast cancer trials.
Oncolytics Biotech (NASDAQ: ONCY) released a letter to shareholders detailing significant progress in its development pipeline during Q1 2022. The company remains on track to announce top-line data for its BRACELET-1 trial in Q4 2022, aimed at advanced HR+/HER2- breast cancer. Their collaboration with Roche in gastrointestinal cancers is on schedule, and they are advancing trials in China for pelareorep. The safety profile of pelareorep is highlighted as a key factor for business development, enhancing its potential in various cancer treatments.
FAQ
What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?
What is the market cap of Oncolytics Biotech Common Shares (ONCY)?
What is Oncolytics Biotech Inc. known for?
What cancers is Oncolytics currently targeting?
What is pelareorep?
What are the recent achievements of Oncolytics Biotech?
How is Oncolytics Biotech funded?
What is the GOBLET study?
What are the potential benefits of pelareorep?
What is the focus of Oncolytics' current clinical trials?
What partnerships does Oncolytics Biotech have?
Where can I find more information about Oncolytics Biotech?
